๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Resectable Lung Non-Small Cell Carcinoma

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC NCT06424899Phase 21 site๐Ÿ“ Hangzhou Zeng Jian ยท Tests: Adebrelimab, radical chemoradiotherapy, Platinum based chemotherapy Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients NCT06634199n/a22 sites๐Ÿ“ Ferrol๐Ÿ“ Alicante๐Ÿ“ Badalona Fundaciรณn GECP ยท Tests: Durvalumab Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer NCT07410975Phase 21 site๐Ÿ“ Shanghai Shanghai Pulmonary Hospital, Shanghai, China ยท Tests: sintilimab+IBI310+chemotherapy Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer NCT05765877Phase 21 site๐Ÿ“ Jinan Pingping Song ยท Tests: WX-0593 Tablets PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC NCT06977074Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: PD-1 inhibitor, Platinum Doublet A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) NCT04302025Phase 238 sites๐Ÿ“ Duarte๐Ÿ“ Irvine๐Ÿ“ Los Angeles Genentech, Inc. ยท Tests: Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) NCT06312137Phase 3270 sites๐Ÿ“ Little Rock๐Ÿ“ Springdale๐Ÿ“ Beverly Hills Merck Sharp & Dohme LLC ยท Tests: Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients NCT06987734Phase 21 site๐Ÿ“ Shanghai Shanghai Pulmonary Hospital, Shanghai, China ยท Tests: Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC๏ผˆneoSCORE โ…ก๏ผ‰ NCT05429463Phase 31 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Sintilimab, Carboplatin, Albumin-Bound Paclitaxel Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations NCT07195695Phase 3202 sites๐Ÿ“ Fresno๐Ÿ“ Glendale๐Ÿ“ Orange Boehringer Ingelheim ยท Tests: Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab Prehabilitation Physical Therapy and Relaxation Intervention Program to Promote Resiliency and Operative Success Among Adults Receiving Lung Cancer Surgery, ROAR-LCS Trial NCT07584239NA1 site๐Ÿ“ Columbus Ohio State University Comprehensive Cancer Center ยท Tests: Biospecimen Collection, Exercise Intervention, Exercise Intervention, Exercise Intervention, Internet-Based Intervention Impact of Surgical Approach on Adaptation of Posture-respiratory Coupling NCT06276530NA1 site๐Ÿ“ Paris Assistance Publique - Hรดpitaux de Paris ยท Tests: EOS imaging for musculoskeletal disorder, Movement analysis by an optoelectronic camera., Stabilometric measurement by โ€ฆ Effects of Infusion Timing on Treatment Response in Solid Tumors NCT07630168Phase 21 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-โ€ฆ Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression NCT06269211Phase 22 sites๐Ÿ“ Guangzhou๐Ÿ“ Shanghai Ruijin Hospital ยท Tests: Toripalimab Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage โ…ข EGFR-mutant Non-small Cell Lung Cancer NCT07323056Phase 21 site๐Ÿ“ Shanghai Shanghai Pulmonary Hospital, Shanghai, China ยท Tests: Sacituzumab Tirumotecan and Limertinib Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH) NCT06437977Phase 31 site๐Ÿ“ Shanghai Shanghai Chest Hospital ยท Tests: SBRT, Toripalimab A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL) NCT07169708n/a9 sites๐Ÿ“ Kaohsiung City๐Ÿ“ Kaohsiung City๐Ÿ“ Kaohsiung City Ono Pharmaceutical Co., Ltd. A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC) NCT07652736n/a6 sites๐Ÿ“ Cรณrdoba๐Ÿ“ Jaรฉn๐Ÿ“ Lugo BeOne Medicines ยท Tests: Tislelizumab Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial NCT06262386NA1 site๐Ÿ“ Taoyuan City Chang Gung Memorial Hospital ยท Tests: Cisplatin based chemottherapy Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC NCT05536505Phase 216 sites๐Ÿ“ Beijing๐Ÿ“ Chongqing๐Ÿ“ Foshan Guangdong Association of Clinical Trials ยท Tests: Adjuvant treatment for MRD positivity Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer NCT07329322Phase 21 site๐Ÿ“ Beijing Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: Sacituzumab Tirumotecan, Osimertinib Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer NCT07855965Phase 29 sites๐Ÿ“ Chengdu๐Ÿ“ Chengdu๐Ÿ“ Chengdu West China Hospital ยท Tests: Cryo-Thermal Ablation, Toripalimab, Platinum-based doublet chemotherapy Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer NCT06008730Phase 21 site๐Ÿ“ Atlanta Emory University ยท Tests: Biospecimen Collection, Proton Beam Radiation Therapy, Radiology, Treatment Planning A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer NCT05913089Phase 210 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Beijing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ยท Tests: TQB2450 injection + Chemotherapy, TQB2450 injection + Anlotinib Hydrochloride Capsule Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage โ…ก-โ…ข Non-small Cell Lung Cancer: A Phase โ…ข, Randomized, Multicenter, Prospective Study NCT06598527Phase 31 site๐Ÿ“ Guangzhou Yang Hong ยท Tests: Stereotactic body radiotherapy (SBRT), Tislelizumab, Chemotherapy Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer NCT06659042Phase 21 site๐Ÿ“ Shanghai Shanghai Chest Hospital ยท Tests: Tislelizumab, Cisplatin, Carboplatin, Pemetrexed Disodium A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer NCT07229729Phase 21 site๐Ÿ“ Guangzhou Shanghai Hengrui Pharmaceutical Co., Ltd. ยท Tests: SHR-A2102, Adebrelimab, Paclitaxel, Carboplatin, Alomnertinib Mesilate AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer NCT05377658Phase 21 site๐Ÿ“ Zhengzhou Henan Cancer Hospital ยท Tests: AK104, Albumin-Bound Paclitaxel, Carboplatin Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC NCT04865250Phase 21 site๐Ÿ“ Heidelberg University Hospital Heidelberg ยท Tests: Atezolizumab 1200 mg abs day 1 q22 (iv) Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3) NCT06926790Phase 21 site๐Ÿ“ Guangzhou The First Affiliated Hospital of Guangzhou Medical Universiโ€ฆ ยท Tests: Nivolumab & Ipilimumab
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy